WO1999061645A1 - Novel compound, wf00144 - Google Patents

Novel compound, wf00144 Download PDF

Info

Publication number
WO1999061645A1
WO1999061645A1 PCT/JP1999/002707 JP9902707W WO9961645A1 WO 1999061645 A1 WO1999061645 A1 WO 1999061645A1 JP 9902707 W JP9902707 W JP 9902707W WO 9961645 A1 WO9961645 A1 WO 9961645A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
reaction
salt
medicament
brown
Prior art date
Application number
PCT/JP1999/002707
Other languages
French (fr)
Inventor
Yoshihiro Ohtsu
Miho Tanaka
Toshihiro Shibata
Kazutoshi Sakamoto
Yasuhisa Tsurumi
Shigehiro Takase
Motohiro Hino
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to JP54687699A priority Critical patent/JP2002510335A/en
Publication of WO1999061645A1 publication Critical patent/WO1999061645A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G3/00—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Definitions

  • the present invention relates to a new bioactive compound, hereinafter entitled WF00144 substance or its salt which is useful as a medicament.
  • the present invention relates to a new bioactive compound, WF00144 substance or its salt.
  • WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, to a process for preparation thereof, to a pharmaceutical composition comprising the same, which is useful as antidiabetic agents, and to a use thereof as a medicament.
  • one object of this invention is to provide a novel compound
  • WF00144 substance which is of use for treating and preventing diabetes, and the like.
  • Another object of this invention is to provide a process for production of the WF00144 substance by fermentation of a WF00144 substance-producing microorganism in a nutrient medium.
  • a further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, the WF00144 substance.
  • Still further object of this invention is to provide a use of the WF00144 substance for treating and preventing diabetes and the like.
  • the WF00144 substance can be produced by fermentation of the WF00144 substance-producing microorganism, especially, strain belonging to the genus Phoma such as Phoma sp. No. 00144 in a nutrient medium.
  • the production of the WF00144 substance is not limited to the use of the particular organism described herein, which is given for the illustrative purpose only.
  • This invention also includes the use of any mutants which are capable of producing the WF00144 substance including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as irradiation of X- ray, ultra-violet radiation, genetic engineering treatment with N-methyl-N'- nitro-N-nitrosoguanidine, 2-aminopurine, and the like.
  • the fungal strain No.00144 was originally isolated from a decayed leaf sample, collected at Ashiwada-mura, Minamitsuru-gun, Yamanashi-ken,
  • the morphological characteristics were determined from the cultures on a Miura's LCA plate (Miura, K. and M. Kudo: Trans. Mycol. Soc. Japan, 11:116-118, 1970).
  • Conidiomata were pycnidial, superficial or immersed, separate and brown to dark brown. Their shape was globose to subglobose, sometimes papillate, distinctly ostiolate, unilocular, and 60-90(-110) x 55-85 ⁇ m in size. Ostioles were 10-30(-35) ⁇ m in diameter.
  • a few pycnidia formed l-3(-5) setae around the ostiole. The setae were dark brown, smooth, thick -walled, unbranched, somewhat flexuous, acute at the apex, and
  • Pycnidial walls were thin and composed of 1-2 cells layer.
  • the cells of pycnidial walls were thick-walled, brown, irregularly shaped, 3.5- 8 x 2.5-6.5 ⁇ m, and formed textura angularis.
  • the inner pycnidial walls formed directly conidiogenous cells without conidiophores.
  • the conidiogenous cells were discrete, acrogenous, hyaline, smooth, ampulliform to lageniform, and 3.5-8 x 2.5-6 ⁇ m.
  • the tips of conidiogenous cells were 1.5- 2.5 ⁇ m wide.
  • Conidia were enteroblastic, phialidic, hyaline, smooth, one- celled, globose to subglobose, with a small projection at the base, and 2.5-3.5 x (2-)2.5-3 ⁇ m.
  • Vegetative hyphae were smooth, septate, brown and branched. The hyphal cells were cylindrical and 1.5-5 ⁇ m in width. Chlamydospores were not observed.
  • Potato dextrose agar G Restrictedly, 2.0-3.0 cm (Difco 0013) S: Circular, plane to raised, felty to cottony, formed many pycnidia, greenish gray (27F2) to dark green (27F3) R:Dark gray (1F1) to reddish gray (12F2), sometimes producing reddish soluble pigments Czapek's solution agar* G:Restrictedly, 2.0-3.0 cm
  • Emerson Yp Ss agar G Very restrictedly, 1.0-2.0 cm (Difco 0739)
  • S Circular, plane, felty, radiately sulcate, formed pycnidia abundantly, dark gray (1F1)
  • Corn meal agar G Restrictedly, 1.5-2.5 cm (Difco 0386)
  • S Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4F2) to olive brown (4F3) at the center, and dark gray (1F1) to dark green (28F4) at the margin
  • Oatmeal agar G Very restrictedly, 1.0-2.0 cm (Difco 0552)
  • S Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4D2-4F2) to olive brown (4F3) at the center, and dark gray (1F1) at the margin
  • G growth, measuring colony size in diameter, S: colony surface, R: reverse.
  • the WF00144 substance is produced when the WF00144 substance- producing strain belonging to the genus Phoma is grown in a nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.).
  • the preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose, glycerin, or the like.
  • the preferred sources of nitrogen are peanut powder, yeast extract, peptone, gluten meal, cotton seed flour, soybean powder, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or amino acid, or the like.
  • ammonium salts e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.
  • urea or amino acid or the like.
  • the carbon and nitrogen sources though advantageously employed in combination, need not to be used in their pure form because less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
  • medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salts, iron salts, or cobalt salts, or the like.
  • a defoaming agent such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone, or the like may be added. Agitation and aeration of the culture mixture may be accomplished in a variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermenter, and the like.
  • the fermentation is usually conducted at a temperature between about
  • the culture broth is then subjected for recovery of the WF00144 substance to various procedures conventionally used for recovery and purification of biological active substance, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.
  • the WF00144 substance obtained can be converted to its salt in a conventional manner.
  • the salt of the WF00144 substance may include a salt with an organic or inorganic base such as alkaline metal salt (e.g. sodium or potassium salt ), alkaline earth metal salt (e.g. calcium or magnesium salt ), organic amine salt (e.g. ethanolamine salt, etc.) amino acid salt (e.g. arginine salt, lysine salt, histidine salt, etc.) and the like.
  • alkaline metal salt e.g. sodium or potassium salt
  • alkaline earth metal salt e.g. calcium or magnesium salt
  • organic amine salt e.g. ethanolamine salt, etc.
  • amino acid salt e.g. arginine salt, lysine salt, histidine salt, etc.
  • the WF00144 substance as obtained has the following physico-chemical properties:
  • the WF00144 substance possesses pharmacological activities such as the inhibitory activity against gluconeogenesis, and the like, and therefore are useful for the treatment and prevention of diabetes, and the like.
  • the WF00144 substance may be useful for various diseases because of its useful pharmaceutical activity such as an inhibitory activity against gluconeogenesis, and so on.
  • Hepatocytes were prepared from 24 hours starved male Wistar rat (150- 200 g) by the collagenase perfusion technique. Cells were cultured in William's E medium containing 5%(v/v) fetal bovine serum, O.lmg/ml kanamycin for 6 hours at 96-well tissue culture plates. Cells were washed with phosphate-buffered saline and incubated with Dulbecco's Modified Eagle's
  • Gluconeogenesis rate was performed as glucose value derived from pyruvate.
  • the half -maximal inhibitory concentration of WF00144 substance on rat hepatocytes gluconeogenesis was 0.08 ⁇ g/ml.
  • the pharmaceutical composition of this invention can be used in the form of pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the WF00144 substance or its pharmaceutically acceptable salt, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations.
  • the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.
  • the carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.
  • the above pharmaceutical composition For applying the above pharmaceutical composition to a patient including human beings and animals suffered from diabetes, it is preferable to apply it by intravenous, intramuscular, topical or oral administration. While the dosage of therapeutically effective amount of the WF00144 substance varies from and also depends upon the age and condition of each individual patient to be treated, the optimal dosage for the treatment of the patient suffered from diabetes may be selected from the range of 0.01 - 50 mg of the WF00144 substance per kg weight of the patient.
  • the cultured broth (20 L; containing 1.8g of WF00144 substance) was filtered with an aid of diatomaceous earth.
  • the filtered mycelium was extracted with 20L of acetone by intermittent mixing for 1 hr.
  • the acetone extract was filtered and diluted with twice volume of deionized water.
  • the diluted filtrate was passed through a column (2L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with 50% aqueous methanol and eluted with 80% methanol.
  • the eluate (4L) was concentrated in vacuo to one liter and added with 3 liters of 0.07% aqueous trifluoroacetic acid, and then applied on a column (2L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid.
  • the column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid.
  • the fractions containing the WF00144 substance were combined and applied on a column (1L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid.
  • the column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid.
  • the fractions containing the WF00144 substance were combined and concentrated in vacuo to give residual water.
  • the residual water was twice extracted with equal volume of ethyl acetate.
  • the extract was concentrated in vacuo to small volume and added with several volumes of n-hexane, and then concentrated in vacuo to give 810mg of crude WF00144 substance as a powder.
  • the 60mg of crude WF00144 powder was dissolved in acetonitrile (0.6ml) and subjected to preparative HPLC, YMC-packed column (ODS-AM SH-343-5AM S-5 (20 mm ⁇ x 250mmL; YMC Co., Ltd.) with 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid as a mobile phase and flow rate of 9.9 ml/min. Elution was monitored by analytical HPLC indicated below. The portion corresponding to the purified WF00144 substance was concentrated in vacuo to give residual water. This residue was twice extracted with equal volume of ethyl acetate and concentrated in vacuo to small volume.
  • the concentrated extract was added with several volumes of n-hexane and dried in vacuo to give 36mg of purified WF00144 substance as a white powder.

Abstract

The present invention provides a new bioactive compound, WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, and a process for production of the same, which comprises culturing a WF00144 substance-producing strain belonging to the genus Phoma in a nutrient medium and recovering the WF00144 substance. Also provided are a pharmaceutical composition containing the WF00144 substance or pharmaceutically acceptable salt thereof, a use of the WF00144 substance as a medicament and use of the WF00144 substance for the manufacture of a medicament for therapeutic treatment or prevention of diabetes in human or animal.

Description

DESCRIPTION
NOVEL COMPOUND, WF00144
TECHNICAL FIELD
The present invention relates to a new bioactive compound, hereinafter entitled WF00144 substance or its salt which is useful as a medicament.
DISCLOSURE OF INVENTION
The present invention relates to a new bioactive compound, WF00144 substance or its salt.
More particularly, it relates to a novel compound, WF00144 substance or its salt which has an inhibitory activity against gluconeogenesis, to a process for preparation thereof, to a pharmaceutical composition comprising the same, which is useful as antidiabetic agents, and to a use thereof as a medicament.
Accordingly, one object of this invention is to provide a novel compound,
WF00144 substance which is of use for treating and preventing diabetes, and the like.
Another object of this invention is to provide a process for production of the WF00144 substance by fermentation of a WF00144 substance-producing microorganism in a nutrient medium.
A further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, the WF00144 substance.
Still further object of this invention is to provide a use of the WF00144 substance for treating and preventing diabetes and the like.
The WF00144 substance can be produced by fermentation of the WF00144 substance-producing microorganism, especially, strain belonging to the genus Phoma such as Phoma sp. No. 00144 in a nutrient medium.
It is to be understood that the production of the WF00144 substance is not limited to the use of the particular organism described herein, which is given for the illustrative purpose only. This invention also includes the use of any mutants which are capable of producing the WF00144 substance including natural mutants as well as artificial mutants which can be produced from the described organism by conventional means such as irradiation of X- ray, ultra-violet radiation, genetic engineering treatment with N-methyl-N'- nitro-N-nitrosoguanidine, 2-aminopurine, and the like.
Characteristics of producing strain No .00144
The fungal strain No.00144 was originally isolated from a decayed leaf sample, collected at Ashiwada-mura, Minamitsuru-gun, Yamanashi-ken,
Japan. This organism grew restrictedly on various culture media, and formed olive brown to dark green colonies. On or in the agar media, the strain produced pycnidial conidiomata. The conidiomata were globose to subglobose, brown, and formed ampulliform conidiogenous cells on their inner walls. Conidia were hyaline, one-celled and globose to subglobose. The strain did not formed teleomorph. Its mycological characteristics were as follows.
Cultural characteristics on various agar media are summarized in Table 1. Culture on potato dextrose agar grew restrictedly, attaining 2.0-3.0 cm in diameter two weeks later at 25°C. This colony surface was plane to raised, felty to cottony, and greenish gray to dark green. Many conidiomata were formed on or in the media. The reverse color was dark gray to reddish gray, and sometimes producing reddish soluble pigments. Colonies on corn meal agar spread more restrictedly than on potato dextrose agar, attaining 1.5-2.5 cm in diameter under the same conditions. The surface was plane, felty, exudate, brownish gray to olive brown at the center, and dark gray to dark green at the margin. The reverse was dark gray to dark green. Conidiomata were abundantly formed.
The morphological characteristics were determined from the cultures on a Miura's LCA plate (Miura, K. and M. Kudo: Trans. Mycol. Soc. Japan, 11:116-118, 1970). Conidiomata were pycnidial, superficial or immersed, separate and brown to dark brown. Their shape was globose to subglobose, sometimes papillate, distinctly ostiolate, unilocular, and 60-90(-110) x 55-85 μm in size. Ostioles were 10-30(-35) μm in diameter. In old culture, a few pycnidia formed l-3(-5) setae around the ostiole. The setae were dark brown, smooth, thick -walled, unbranched, somewhat flexuous, acute at the apex, and
15-24 x 4-6μm. Pycnidial walls were thin and composed of 1-2 cells layer. The cells of pycnidial walls were thick-walled, brown, irregularly shaped, 3.5- 8 x 2.5-6.5 μm, and formed textura angularis. The inner pycnidial walls formed directly conidiogenous cells without conidiophores. The conidiogenous cells were discrete, acrogenous, hyaline, smooth, ampulliform to lageniform, and 3.5-8 x 2.5-6 μm. The tips of conidiogenous cells were 1.5- 2.5 μm wide. Conidia were enteroblastic, phialidic, hyaline, smooth, one- celled, globose to subglobose, with a small projection at the base, and 2.5-3.5 x (2-)2.5-3 μm. Vegetative hyphae were smooth, septate, brown and branched. The hyphal cells were cylindrical and 1.5-5 μm in width. Chlamydospores were not observed.
Strain No .00144 was able to grow at the temperature range from 5 to 30°C, with the growth optimum at 21 to 24°C. These temperature data were determined on potato dextrose agar (made by NISSUI). On the basis of comparing the morphological characteristics with fungal taxonomic criteria by von Arx (J. A. von Arx: The Genera of Fungi - Sporulating in Pure Culture. 3rd ed., pp.315, J. Cramer, Vaduz, 1974) and by Sutton (B . C. Sutton: The Coelomycetes - Fungi Imperfecti with Pycnidia, Acervuli and Stroma., pp.696, Commonwealth Mycological Institute, Kew, 1980.), strain No .00144 was considered to belong to the coelomycete genus
Phoma Sacc. 1880 (Sphaeropsidales). Thus, we identified this isolate as one strain of the genus Phoma , and named it Phoma sp. No .00144. The strain has been deposited to the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, at 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki, Japan, as FERM BP-6360 (deposited date : May 19,
1998) under the Budapest Treaty. Table 1. Cultural characteristics of strain No .00144.
Media Cultural characteristics
Malt extract agar* G:Rather restrictedly, 2.5-3.5 cm
S: Circular, plane, felty, radiately sulcate, sometimes exudate, formed some pycnidia, dark green (28F3-28F4) to dull green (28D3-28E3) R: Grayish brown (8F3) to dark brown
(8F4-8F5), sometimes producing reddish soluble pigments
Potato dextrose agar G:Restrictedly, 2.0-3.0 cm (Difco 0013) S: Circular, plane to raised, felty to cottony, formed many pycnidia, greenish gray (27F2) to dark green (27F3) R:Dark gray (1F1) to reddish gray (12F2), sometimes producing reddish soluble pigments Czapek's solution agar* G:Restrictedly, 2.0-3.0 cm
S: Circular, plane or somewhat raised, felty, radiately sulcate or wrinkly, exudate, formed pycnidia abundantly, olive (1F3-1E4) to olive gray (1F2), and reddish brown (8E3-8E5) at the margin
R:Dark brown (8F3-8F4), and light brown (7D4) to brown (7E4) at the margin, sometimes producing orange soluble pigments Sabouraud dextrose agar G:Restrictedly, 2.0-3.0 cm
(Difco 0190) S: Circular, plane to centrally raised, felty, radiately sulcate, formed no pycnidia, dull green (28 E4) to dark green (28 F3), and greenish gray (28D2) at the margin R:Dark ruby (12F3) to dark purple (14F3), sometimes producing reddish soluble pigments
Emerson Yp Ss agar G:Very restrictedly, 1.0-2.0 cm (Difco 0739) S: Circular, plane, felty, radiately sulcate, formed pycnidia abundantly, dark gray (1F1)
R:Dark gray (1F1) to dark blue (22F4)
Corn meal agar G:Restrictedly, 1.5-2.5 cm (Difco 0386) S: Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4F2) to olive brown (4F3) at the center, and dark gray (1F1) to dark green (28F4) at the margin
R:Dark gray (1F1) to dark green (28F4)
MY20 agar* G .-Restrictedly, 1.5-2.5 cm
S: Circular, plane, felty, sometimes funiculose, radiately sulcate or wrinkly, formed no pycnidia, dull green (28D3-28E3) or brownish gray (4E2) to olive brown (4E3)
R: Grayish brown (7F3) to dark brown (7F4), and light brown (7D4) to brown (7E4) at the margin, sometimes producing pale orange soluble pigments
Oatmeal agar G:Very restrictedly, 1.0-2.0 cm (Difco 0552) S: Circular, plane, felty, exudate, abundantly formed pycnidia, brownish gray (4D2-4F2) to olive brown (4F3) at the center, and dark gray (1F1) at the margin
Abbreviation G: growth, measuring colony size in diameter, S: colony surface, R: reverse.
* : The compositions of malt extract agar, Czapek's solution agar and MY20 agar were based on JCM Catalogue of Strains (Nakase, T., 6th ed., pp.617, Japan Collection of Microorganisms, the Institute of Physical and Chemical Research, Saitama, 1995). These characteristics were observed after 14 days of incubation at 25°C. The color descriptions were based on Methuen Handbook of Colour (Kornerup, A. and J. H. Wanscher, 3rd ed., pp.252, Methuen, London, 1978).
Production of the WF00144 substance
The WF00144 substance is produced when the WF00144 substance- producing strain belonging to the genus Phoma is grown in a nutrient medium containing sources of assimilable carbon and nitrogen under aerobic conditions (e. g. shaking culture, submerged culture, etc.).
The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, sucrose, starch, fructose, glycerin, or the like.
The preferred sources of nitrogen are peanut powder, yeast extract, peptone, gluten meal, cotton seed flour, soybean powder, soybean meal, corn steep liquor, dried yeast, wheat germ, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e. g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea or amino acid, or the like.
The carbon and nitrogen sources, though advantageously employed in combination, need not to be used in their pure form because less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, zinc salts, iron salts, or cobalt salts, or the like.
If necessary, especially when the culture medium foams seriously a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone, or the like may be added. Agitation and aeration of the culture mixture may be accomplished in a variety of ways, such as agitation by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermenter, and the like.
The fermentation is usually conducted at a temperature between about
10 °C and 40 °C, preferably 20 °C to 35 °C, for a period of about 24 hours to 120 hours, which may be varied according to fermentation conditions and scales.
When the fermentation is completed, the culture broth is then subjected for recovery of the WF00144 substance to various procedures conventionally used for recovery and purification of biological active substance, for instance, solvent extraction with an appropriate solvent or a mixture of some solvents, chromatography or recrystallization from an appropriate solvent or a mixture thereof.
The WF00144 substance obtained can be converted to its salt in a conventional manner. The salt of the WF00144 substance may include a salt with an organic or inorganic base such as alkaline metal salt (e.g. sodium or potassium salt ), alkaline earth metal salt (e.g. calcium or magnesium salt ), organic amine salt (e.g. ethanolamine salt, etc.) amino acid salt (e.g. arginine salt, lysine salt, histidine salt, etc.) and the like.
The WF00144 substance as obtained has the following physico-chemical properties:
(1) Appearance: white powder (2) Molecular formula : 2 H40U9
(3) Elementary Analysis:
Calcd for C27H40O9 ■ 1/2H20 C 62.65, H 7.98 Found:
C 62.22, H 7.97
(4) Molecular weight:
ESI-MS(negative): m/z 507 (M-H)~ (Calcd .Molecular weight: 508.61) (5) Melting point:
85T89 °C (dec)
(6) Optical rotation:
[α]D(23°C) =-16 ° (c=0.2, in chloroform)
(7) Ultraviolet absorption spectrum: λmax (methanol): 275 nm (ε =8000) (8) Solubility: Soluble: acetonitrile, chloroform, ethyl acetate, dimethylsulfoxide Slightly soluble: n-hexane Insoluble: water
(9) Color reaction: Positive: cerium sulfate reaction, iodine vapor reaction, Negative: Molish's reaction, ninhydrin reaction, Dragendorff reaction,
Ehrlich's reaction
(10) Thin layer chromatography (TLC):
Stationary phase Developing solvent Rf value
Silica Gel 60 n-hexane : ethyl acetate : acetic acid 0.25 F254* ( 50: 50: l, v/v )
* made by E. Merck
(11) High Performance Liquid Chromatography (HPLC): Condition:
Column: YMC-Pack Pro C18 AS-302 * *(4.6 mmφ x 150mmL) Mobile phase: 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate: 1 ml/min
Detection: UV at 280 nm
Retention time: 7.9 min * *: made by YMC Co., Ltd.
(12) Infrared absorption spectrum: vmax (KBr): 3480, 2980, 2930, 1730, 1710, 1650, 1620, 1460, 1380, 1160, 1140 cm 1
(13) JH Nuclear magnetic resonance spectrum: (500 MHz, CD3CN) δ(ppm):
15.0 (IH, br s), 7.76 (IH, d, 5), 5.97 (IH, d, 5), 5.74 (IH, br s), 4.22 (IH, dd, 10.5, 9.5), 4.13 (IH, dd, 10.5, 4.5), 3.20 - 3.13 (2H, m), 2.63 (IH, m), 2.53 (IH, dd, 13, 10), 2.18 (IH, m), 2.12 (3H, br s), 2.02 (IH, m), 1.85 (IH, s), 1.80 (IH, m), 1.53 (3H, s), 1.57 - 1.47 (2H, m), 1.37 (IH, m), 1.27 (IH, m), 1.27 (3H, s), 1.16 (3H, s), 1.12 (IH, dd, 12, 14), 0.82 (3H, t, 7), 0.68 (3H, d, 6.5).
(14) 13C Nuclear magnetic resonance spectrum: (125 MHz, CDCN) δ(ppm):
217.4 (s), 209.3 (s), 173.5 (d), 170.9 (s), 167.5 (s), 153.5 (s), 119.7 (d), 102.7 (d), 78.1 (s), 69.6 (t), 68.9 (s), 50.5 (d), 50.2 (s), 48.4 (t), 46.4 (t), 45.7 (d), 41.9 (t), 41.5 (d), 41.3 (d), 31.0 (q), 30.1 (d), 24.6 (q), 22.5 (t),21.3 (q), 20.6 (q), 19.1 (q), 13.4 (q).
(15) Nature of substance: acidic substance.
Biological properties of the WF00144 substance
The WF00144 substance possesses pharmacological activities such as the inhibitory activity against gluconeogenesis, and the like, and therefore are useful for the treatment and prevention of diabetes, and the like.
And further, the WF00144 substance may be useful for various diseases because of its useful pharmaceutical activity such as an inhibitory activity against gluconeogenesis, and so on.
As examples for showing biological activities of the WF00144 substance, some biological data are explained in the following.
Test (Effect of WF00144 substance on rat hepatocytes gluconeogenesis)
Hepatocytes were prepared from 24 hours starved male Wistar rat (150- 200 g) by the collagenase perfusion technique. Cells were cultured in William's E medium containing 5%(v/v) fetal bovine serum, O.lmg/ml kanamycin for 6 hours at 96-well tissue culture plates. Cells were washed with phosphate-buffered saline and incubated with Dulbecco's Modified Eagle's
Medium without glucose, supplemented with 20mM pyruvate, lxlO"7 M glucagon, O.lmg/ml kanamycin and l%(v/v) fetal bovine serum. After 15 hours, glucose produced into the medium was determined by enzymatically method. Gluconeogenesis rate was performed as glucose value derived from pyruvate. The half -maximal inhibitory concentration of WF00144 substance on rat hepatocytes gluconeogenesis was 0.08μg/ml.
The pharmaceutical composition of this invention can be used in the form of pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the WF00144 substance or its pharmaceutically acceptable salt, as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral administrations. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, injections, ointments, liniments, eye drops, lotion, gel, cream, and any other form suitable for use.
The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, solubilizing and coloring agents and perfumes may be used.
For applying the above pharmaceutical composition to a patient including human beings and animals suffered from diabetes, it is preferable to apply it by intravenous, intramuscular, topical or oral administration. While the dosage of therapeutically effective amount of the WF00144 substance varies from and also depends upon the age and condition of each individual patient to be treated, the optimal dosage for the treatment of the patient suffered from diabetes may be selected from the range of 0.01 - 50 mg of the WF00144 substance per kg weight of the patient.
The following examples are given for the purpose of illustrating the present invention.
Example 1:
(1) Fermentation of Phoma sp. No.00144 for the production of the WF00144 substance An aqueous seed medium (30ml) containing sucrose 4%, glucose 1%, soluble starch 2%, cotton seed meal 3%, soybean flour 1.5%, KH2P04 1%, CaC03 0.2% was placed in a 100-ml Erlenmeyer flask and was sterilized at 121°C for 30 minutes. A loopful of a slant culture of Phoma sp. No.00144 was inoculated in a seed flask. The inoculated flask was shaken on a rotary shaker
(220 rpm, 5.1 cm throw) at 25°C for 4 days, and 3.2ml of the seed culture was transferred to 160-ml of the same sterile seed medium in the 500 ml Erlenmeyer flasks. The flasks were shaken on a rotary shaker (220rρm, 5.1 cm throw) at 25 °C for 4 days, and 480 ml (three flasks) of second seed culture was inoculated to 20 liters of sterile production medium containing of glucose
1 %, starch acid hydrolysates 3%, wheat germ 1%, KH2P04 1%, Adecanol LG- 109 (deforming agent, Asahi Denka Co., Ltd.) 0.05%, Silicone KM-70 (deforming agent, Shin-Etsu Chemical Co., Ltd.) 0.05% in a 30-liter jar fermentor. Fermentation was carried out at 25 °C for 7 days under aeration of 20 liters / minute and agitation of 400rpm.
The production of the WF00144 substance in the fermentation broth was monitored by HPLC analysis indicated below.
Analytical condition: Column; YMC-Pack Pro C18 AS-302 (4.6 mmφ x 150mmL, made by YMC
Co., Ltd.)
Mobile phase; 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate; lml/min
Detection; UV at 280nm Retention time: 7.9min.
(2) Isolation of WF00144 substance
The cultured broth (20 L; containing 1.8g of WF00144 substance) was filtered with an aid of diatomaceous earth. The filtered mycelium was extracted with 20L of acetone by intermittent mixing for 1 hr. The acetone extract was filtered and diluted with twice volume of deionized water. The diluted filtrate was passed through a column (2L) of Diaion HP-20 (Mitsubishi Chemical Co., Ltd.). The column was washed with 50% aqueous methanol and eluted with 80% methanol. The eluate (4L) was concentrated in vacuo to one liter and added with 3 liters of 0.07% aqueous trifluoroacetic acid, and then applied on a column (2L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid. The column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid. The fractions containing the WF00144 substance were combined and applied on a column (1L) of YMC GEL ODS-AM 120-S-50 (YMC Co., Ltd.) packed with 25% aqueous acetonitrile containing 0.05% trifluoroacetic acid. The column was washed with 30% acetonitrile containing 0.05% trifluoroacetic acid, 40% acetonitrile containing 0.05% trifluoroacetic acid and eluted with 50% acetonitrile containing 0.05% trifluoroacetic acid. The fractions containing the WF00144 substance were combined and concentrated in vacuo to give residual water. The residual water was twice extracted with equal volume of ethyl acetate. The extract was concentrated in vacuo to small volume and added with several volumes of n-hexane, and then concentrated in vacuo to give 810mg of crude WF00144 substance as a powder.
The 60mg of crude WF00144 powder was dissolved in acetonitrile (0.6ml) and subjected to preparative HPLC, YMC-packed column (ODS-AM SH-343-5AM S-5 (20 mmφ x 250mmL; YMC Co., Ltd.) with 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid as a mobile phase and flow rate of 9.9 ml/min. Elution was monitored by analytical HPLC indicated below. The portion corresponding to the purified WF00144 substance was concentrated in vacuo to give residual water. This residue was twice extracted with equal volume of ethyl acetate and concentrated in vacuo to small volume.
The concentrated extract was added with several volumes of n-hexane and dried in vacuo to give 36mg of purified WF00144 substance as a white powder.
Analytical condition:
Column; YMC-Pack Pro C18 AS-302 (4.6 mmφ x 150mmL)
Mobile phase; 50% aqueous acetonitrile containing 0.05% trifluoroacetic acid
Flow rate; 1 ml/min
Detection; UV at 280nm Retention time ; 7.9min.

Claims

1. WF00144 substance of the following physico-chemical properties or its salt:
(1) Molecular formula : 27H40U9
(2) Elementary Analysis:
Calcd for C27H40O9- l/2H2O C 62.65, H 7.98
Found:
C 62.22, H 7.97
(3) Molecular weight:
ESI-MS(negative): m/z 507 (M-H)~ (Calcd .Molecular weight : 508.61)
(4) Melting point:
85-89 ┬░C (dec)
(5) Optical rotation:
[╬▒]D(23┬░Q =-16 ┬░ (c=0.2, in chloroform) (6) Ultraviolet absorption spectrum: ╬╗max (methanol): 275 nm (╬╡=8000)
(7) Solubility:
Soluble: acetonitrile, chloroform, ethyl acetate, dimethylsulfoxide Slightly soluble: n-hexane Insoluble: water
(8) Color reaction:
Positive: cerium sulfate reaction, iodine vapor reaction, Negative: Molish's reaction, ninhydrin reaction, Dragendorff reaction, Ehrlich's reaction (9) Infrared absorption spectrum: vmax (KBr): 3480, 2980, 2930, 1730, 1710, 1650, 1620, 1460, 1380, 1160, 1140 cm 1 (10) 2H Nuclear magnetic resonance spectrum: (500 MHz, CD3CN) ╬┤(ppm): 15.0 (IH, br s), 7.76 (IH, d, 5), 5.97 (IH, d, 5), 5.74 (IH, br s),
4.22 (IH, dd, 10.5, 9.5), 4.13 (IH, dd, 10.5, 4.5), 3.20 - 3.13 (2H, m), 2.63 (IH, m), 2.53 (IH, dd, 13, 10), 2.18 (IH, m), 2.12 (3H, br s), 2.02 (IH, m), 1.85 (IH, s), 1.80 (IH, m), 1.53 (3H, s), 1.57 - 1.47 (2H, m), 1.37 (IH, m), 1.27 (IH, m), 1.27 (3H, s), 1.16 (3H, s), 1.12 (IH, dd, 12, 14), 0.82 (3H, t, 7), 0.68 (3H, d, 6.5).
(11) 13C Nuclear magnetic resonance spectrum: (125 MHz, CDCN) ╬┤(ppm):
217.4 (s), 209.3 (s), 173.5 (d), 170.9 (s), 167.5 (s), 153.5 (s), 119.7 (d), 102.7 (d), 78.1 (s), 69.6 (t), 68.9 (s), 50.5 (d), 50.2 (s), 48.4 (t), 46.4 (t), 45.7 (d), 41.9 (t), 41.5 (d), 41.3 (d), 31.0 (q),
30.1 (d), 24.6 (q), 22.5 (t),21.3 (q), 20.6 (q), 19.1 (q), 13.4 (q).
2. A process for production of the WF00144 substance or its salt, which comprises culturing a WF00144 substance -producing microorganism in a nutrient medium and recovering the WF00144 substance or its salt from the resultant cultured broth.
3. Biological pure culture of Phoma sp. No. 00144 (FERM BP-6360).
4. A pharmaceutical composition containing the WF00144 substance or pharmaceutically acceptable salt thereof.
5. A use of the WF00144 substance as a medicament.
6. A method for treating or preventing diabetes which comprises administrating the WF00144 substance to human or animal.
7. Use of the WF00144 substance for the manufacture of a medicament for therapeutic treatment or prevention of diabetes in human or animal.
PCT/JP1999/002707 1998-05-28 1999-05-21 Novel compound, wf00144 WO1999061645A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP54687699A JP2002510335A (en) 1998-05-28 1999-05-21 New compound WF00144

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP3771 1998-05-28
AUPP3771A AUPP377198A0 (en) 1998-05-28 1998-05-28 Novel compound WF00144

Publications (1)

Publication Number Publication Date
WO1999061645A1 true WO1999061645A1 (en) 1999-12-02

Family

ID=3808018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/002707 WO1999061645A1 (en) 1998-05-28 1999-05-21 Novel compound, wf00144

Country Status (3)

Country Link
JP (1) JP2002510335A (en)
AU (1) AUPP377198A0 (en)
WO (1) WO1999061645A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091436A1 (en) * 2002-04-26 2003-11-06 Fujisawa Pharmaceutical Co., Ltd. Novel 35 kd protein
CN110878325A (en) * 2019-12-16 2020-03-13 赵兰坤 Optimized glutamic acid fermentation medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149631A (en) * 1993-11-30 1995-06-13 Nkk Corp Inhibitor of aldose reductase
GB2323845A (en) * 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149631A (en) * 1993-11-30 1995-06-13 Nkk Corp Inhibitor of aldose reductase
GB2323845A (en) * 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 123, no. 15, 9 October 1995, Columbus, Ohio, US; abstract no. 188618, YAMADA, MASASHI ET AL: "Aldose reductase inhibitors containing 2-hydroxy-p-benzoquinones" XP002110276 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091436A1 (en) * 2002-04-26 2003-11-06 Fujisawa Pharmaceutical Co., Ltd. Novel 35 kd protein
EP1498487A1 (en) * 2002-04-26 2005-01-19 Fujisawa Pharmaceutical Co., Ltd. Novel 35 kd protein
EP1498487A4 (en) * 2002-04-26 2006-11-29 Astellas Pharma Inc Novel 35 kd protein
US7371842B2 (en) 2002-04-26 2008-05-13 Astellas Pharma Inc. Polynucleotide encoding a 35 KDA protein thats binds to WF00144
CN110878325A (en) * 2019-12-16 2020-03-13 赵兰坤 Optimized glutamic acid fermentation medium
CN110878325B (en) * 2019-12-16 2021-05-25 呼伦贝尔东北阜丰生物科技有限公司 Optimized glutamic acid fermentation medium

Also Published As

Publication number Publication date
AUPP377198A0 (en) 1998-06-18
JP2002510335A (en) 2002-04-02

Similar Documents

Publication Publication Date Title
EP0431350B1 (en) New polypeptide compound and a process for preparation thereof
EP0352646B1 (en) Fr901228 substance and preparation thereof
US5037809A (en) Antimicrobial agent, FR109615 and production thereof
US5854276A (en) Substance WF16616, process for production thereof, and use thereof
KR970009151B1 (en) Ws-9326a, ws-9326b, and their derivatives
WO1999061645A1 (en) Novel compound, wf00144
US6730776B1 (en) WF14573 or its salt, production thereof and use thereof
EP1087987B1 (en) A compound, wf002, production thereof and use thereof
EP0318254B1 (en) Tripeptide derivatives
EP0380373B1 (en) Polycyclic compounds and their production
US4803074A (en) FR-900848 substance and preparation thereof
US4910017A (en) New compounds WF 2015 A and B
EP0504711B1 (en) Compound UCA1064-B
WO2001029182A1 (en) Novel compound, wf217
WO1999063102A1 (en) ANTIDIABETIC ACTIVE COMPOUND(S) WF19353 AND PROCESS FOR THEIR FERMENTATIVE PREPARATION USING A FUNGUS OF THE GENUS $i(HELICOMYCES)
US4670259A (en) Compound FR-68504, production thereof and use thereof
EP0333177A2 (en) FR-900493 substance, a process for its production and a pharmaceutical composition containing the same
WO1995018142A1 (en) Wf15604 substances
JP3176672B2 (en) Novel glutarimide antibiotic having antiviral activity and method for producing the same
EP1489187A1 (en) Osteoclast differentiation inhibitors
JP2000053674A (en) Ec1007 compound
JPH05194525A (en) Reveromycin b, c and c, their production, antitumor agent and antimycotic agent
JPH08176157A (en) New physiologically active substance epostatin, its production and use
GB2293379A (en) WF17819 substance
JPH0931088A (en) Wb968 substance group and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase